ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)

HKD 5.36

(-1.83%)

Total Liabilities Summary of ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s latest annual total liabilities in 2023 was 126.3 Million CNY , up 107.88% from previous year.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s latest quarterly total liabilities in 2024 Q2 was 143.02 Million CNY , down 0.0% from previous quarter.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported annual total liabilities of 60.75 Million CNY in 2022, down -97.56% from previous year.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported annual total liabilities of 2.49 Billion CNY in 2021, down 0.0% from previous year.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported quarterly total liabilities of 143.02 Million CNY for 2024 Q2, down 0.0% from previous quarter.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported quarterly total liabilities of 126.3 Million CNY for 2023 Q4, down 0.0% from previous quarter.

Annual Total Liabilities Chart of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (2023 - 2021)

Historical Annual Total Liabilities of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (2023 - 2021)

Year Total Liabilities Total Liabilities Growth
2023 126.3 Million CNY 107.88%
2022 60.75 Million CNY -97.56%
2021 2.49 Billion CNY 0.0%

Peer Total Liabilities Comparison of ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Name Total Liabilities Total Liabilities Difference
Uni-Bio Science Group Limited 152.81 Million HKD 17.351%
CK Life Sciences Int'l., (Holdings) Inc. 7.05 Billion HKD 98.211%